Clinical Trials · NCT04964934
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- AstraZeneca
- Enrollment
- 315
- Start date
- Jun 2021
- Locations
- 265 sites, 23 countries
- Primary endpoint
- Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)